195 related articles for article (PubMed ID: 33086776)
1. Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome.
Jung HA; Jung CW; Jang JH
Korean J Intern Med; 2021 Mar; 36(2):413-423. PubMed ID: 33086776
[TBL] [Abstract][Full Text] [Related]
2. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
3. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
5. [Outcomes of DNMT3A
Chen YY; Shi R; Guo SQ; Zhang YX; Li YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1292-1297. PubMed ID: 32798414
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
7. NPM1 mutation with DNMT3A wild type defines a subgroup of MDS with particularly favourable outcomes after decitabine therapy.
Wu L; Li X; Xu F; Wu D; He Q; Song L; Xiao C; Zhao Y; Zhang Z; Guo J; Zhou L; Su J; Chang C
Br J Haematol; 2020 Jun; 189(5):982-984. PubMed ID: 32266961
[No Abstract] [Full Text] [Related]
8. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
[TBL] [Abstract][Full Text] [Related]
9. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
10. Why methylation is not a marker predictive of response to hypomethylating agents.
Voso MT; Santini V; Fabiani E; Fianchi L; Criscuolo M; Falconi G; Guidi F; Hohaus S; Leone G
Haematologica; 2014 Apr; 99(4):613-9. PubMed ID: 24688109
[TBL] [Abstract][Full Text] [Related]
11. [Epigenetic dysregulation in myelodysplastic syndromes].
Sashida G
Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
[TBL] [Abstract][Full Text] [Related]
12. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
Du M; Zhou F; Jin R; Hu Y; Mei H
Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine.
Xiu C; Li X; Wu L; Xu F; He Q; Zhang Z; Wu D; Song L; Su J; Zhou L; Zhao Y; Tao Y; Chang C
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3089-3097. PubMed ID: 31559495
[TBL] [Abstract][Full Text] [Related]
14. High expression of the human equilibrative nucleoside transporter 1 gene predicts a good response to decitabine in patients with myelodysplastic syndrome.
Wu L; Shi W; Li X; Chang C; Xu F; He Q; Wu D; Su J; Zhou L; Song L; Xiao C; Zhang Z
J Transl Med; 2016 Mar; 14():66. PubMed ID: 26944860
[TBL] [Abstract][Full Text] [Related]
15. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.
Daskalakis M; Nguyen TT; Nguyen C; Guldberg P; Köhler G; Wijermans P; Jones PA; Lübbert M
Blood; 2002 Oct; 100(8):2957-64. PubMed ID: 12351408
[TBL] [Abstract][Full Text] [Related]
17. Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents.
Sekeres MA
Leuk Lymphoma; 2015; 56(12):3267-9. PubMed ID: 26077360
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.
Leone G; Voso MT; Teofili L; Lübbert M
Clin Immunol; 2003 Oct; 109(1):89-102. PubMed ID: 14585280
[TBL] [Abstract][Full Text] [Related]
19. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
20. [A preliminary study on the outcome of lower-risk myelodysplastic syndrome by low-dose decitabine].
Ye L; Ren YL; Xie LL; Luo YW; Lin PP; Zhou XP; Ma LY; Mei C; Xu WL; Wei JY; Jiang HF; Zhang LM; Zeng H; Tong HY
Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):307-312. PubMed ID: 28468092
[No Abstract] [Full Text] [Related]
[Next] [New Search]